Volume 1 • Issue 3 • 2012 33 x109/L and blasts were 45% in peripheral blood. He was confirmed to have leukemic transformation of his MF. Due to his age and poor performance status, he was treated with azacitidine 75mg/m2 daily for 7 days starting from 9 December 2010. At the start of treatment, his hemoglobin level was 10.9 g/dL, white cell count was 12.0 x109/L, platelet count was 20 x109/L an...

Therapy planning in patients with myelodysplastic syndromes (MDSs) is complicated by its high prognostic heterogeneity. Forty-one patient and disease characteristics at onset of 370 patients with MDS were analyzed to identify significant prognostic factors for survival and transformation to acute myeloblastic leukemia (AML), and to develop and validate a regression model for predicting survival...

Mixed phenotype acute leukemia is a rare subtype of leukemia that probably arises from a hematopoietic pluripotent stem cell. The co-expression of two of myeloid, B- or T-lymphoid antigens is the hallmark of this disease. Herein, the case of a 28-year-old female patient is reported who presented with hemoglobin of 5.8g/dL, white blood cell count of 138×10(9)/L and platelet count of 12×10(9)/L. ...

We report five patients who had greater than 30% peripheral blasts and less than 30% marrow blasts. By the current standards these cases would be classified as myelodysplastic syndrome. Four of five patients progressed to acute leukemia within approximately 1 1/2 months of developing greater than 30% peripheral blasts. Two of these four patients had evidence of acute leukemia by criteria other ...

In 2002, the WHO classification reduced the proportion of blasts in the bone marrow (BM) necessary for the diagnosis of acute myeloid leukemia (AML) from 30% to 20%, eliminating the RAEB-t subtype of myelodysplastic syndromes (MDS). However, this AML subtype, defined as low-blast count AML (LBC-AML, with 20-30% BM-blasts) is characterized by peculiar features, as increased frequency in elderly ...

When presenting, the haemoglobin level was 8.1 g/dl, reticulocytes 0.4%, white blood cell count 17.6 × 10 cells/l with 4% blast cells, 2% myelocytes, 77% polymorphonuclear leukocytes, 5% band cells, 6% monocytes and 7% lymphocytes. The platelet count was 30 × 10/l. Further laboratory tests revealed a lactate dehydrogenase (LDH) level of 251 U/l (normal < 250 U/l), a serum ferritin level of 4720...

Induction chemotherapy is often the first therapeutic intervention for acute myeloid leukemia (AML). Evaluation of post induction bone marrow provides critical information for clinical management; in general increased blast counts or increased marrow cellularity is an ominous sign, suggestive of ineffective therapy, and may warrant additional rounds of chemotherapy. However, increased blasts al...

Induction chemotherapy is often the first therapeutic intervention for acute myeloid leukemia (AML). Evaluation of post induction bone marrow provides critical information for clinical management; in general increased blast countsor increased marrow cellularity is an ominous sign, suggestive of ineffective therapy, and may warrant additional rounds of chemotherapy. However, increased blasts alo...